OneMedNet

ONMD

Market cap $32.6M

MINNEAPOLIS, June 10, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), today announced it has secured more than $3 million in new bookings to date for 2026 as of this announcement – surpassing the Company's total bookings for all of full-year 2025. The Company expects to recognize substantially all of these bookings as revenue by the end of the third quarter of 2026.

MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), today announced that its OneMedNet iRWD™ Network, has surpassed 90 million patient journeys and 270 million studies, with a healthcare partner network now exceeding 2,300 sites. The milestone represents direct progress against the strategic priorities the Company laid out to shareholders at the close of 2025, when OneMedNet identified expansion of its data network as a core pillar of long-term value creation.

MINNEAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), today announced that its OneMedNet iRWD™ Platform, built on Palantir Foundry, is now live and fully operational. This major commercialization milestone delivers searchable access to billions of records across 80 million patient journeys in seconds, transforming how life sciences organizations access and analyze multi-modal clinical data at unprecedented scale and speed.

OneMedNet Announces Strong 2025 Financials and Advances AI-Driven iRWD™ powered by Palantir Foundry enabling Conversational Search on Real-Time Medical Dat

OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and A

MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), today announced a strategic collaboration with Navidence to help research organizations transform rapidly expanding healthcare data into clear, actionable real-world evidence. What This Collaboration Means for the Pharma Market Pharmaceutical companies face growing pressure to integrate high-quality RWD for regulatory submissions, post-market surveillance, and AI model training.

OneMedNet (NASDAQ: ONMD) shares are trading lower on Tuesday, possibly on continued weakness after the stock rallied on Friday following a recent announcement about the next phase of its real-world data (RWD) platform.

MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively converting customer evaluations into commercial subscriptions.

MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic partnership with ViuHealth, a digital health company specializing in autoimmune disease populations. This partnership expands OneMedNet's autoimmune clinical ontology, to the OneMedNet iRWD™ platform—powered by Palantir Foundry—further increasing the scale, diversity, and longitudinal depth of its regulatory-grade Real-World Data.

MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic data licensing agreement with Risorius Co., Ltd., a neurotechnology company developing EEG-based digital biomarkers and AI-powered research platforms for central nervous system (CNS) indications across neurology, psychiatry, and sleep.